Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
CVRX US​

CVRx, Inc.(CVRX US)

$1.42+0.053.65%Ext:$1.30-0.128.54%(Market Closed · 23:56:33 UTC)

Overview

Profile

Financials & Metrics

FinancialsChartingShort InterestEmployees

CVRx, Inc. — Company Profile

CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.

Sector
Industrials
Industry
Commercial Services & Supplies
Exchange
UQ
CEO
Kevin Hykes
Headquarters
Minneapolis, MN, US
IPO Date
Jun 30, 2021
Employees
223
Website
www.barostim.com

Key Metrics

Price
$1.55
Market Cap
$41.13M
Revenue (TTM)
$14.77M
Net Income (TTM)
$-13120000.00
EPS (TTM)
-0.50
P/E (TTM)
-0.78
P/B (TTM)
1.41
Dividend Yield
0.00%
ROE (TTM)
-45.07%
ROA (TTM)
-13.16%
Operating Margin
-82.34%
Beta
1.10

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.

Website
www.barostim.com
Location
Minneapolis, MN, US
Phone763 416 2840
Employees223
CEOKevin Hykes
Sector
Industrials
Industry
Commercial Services & Supplies
IPO DateJun 30, 2021

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

News

  • CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 202622 Oct
  • HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop1 Oct
  • CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 202629 Sep
  • HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop23 Sep
  • CVRx Appoints John Landry as Chief Financial Officer21 Sep
  • HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop10 Sep
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX3 Sep
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX1 Sep
  • CVRx Secures Devoted Health Coverage for Barostim Therapy28 Aug
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims27 Aug
  • HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop26 Aug
  • INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX25 Aug
  • CVRx Responds to Letter from Pointillist Family Office25 Aug
  • CVRx, Inc. Investors Who Suffered Losses Should Contact Block & Leviton LLP24 Aug
  • Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer24 Aug
  • CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy24 Aug
  • HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop19 Aug
  • CVRx, Inc. Investigated For Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the Firm18 Aug
  • HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop13 Aug
  • CVRX ALERT: Securities Fraud Investigation by Block & Leviton Could Allow CVRx, Inc. Investors to Recover Losses13 Aug

Key Stats

Trading

Px/Chg 1D$1.55 / +1.31%
Avg Volume332.02K
Beta1.10
Mkt Cap41.13M
FD Mkt Cap75.36M

Float

Shrs Out/Float26.54M / 18.33M
Short Float0.10%
Days to Cover5.36
Stock Repurchased$43.00K

Current Valuation

EV28.22M
EV/EBITDA-0.60
EV/Sales0.48
P/B1.41
P/S0.70
FCF Yield-29.87%
ROE-45.07%
ROA-13.16%
Current Ratio10.20

Estimates

P/E-0.78
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMay '23May '24May '25May '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-6.20-6.00-3.67-2.93-15.20-3.17
Price / Sales6.5011.073.853.4311.322.82
Price / Book Value2.562.281.992.474.611.43
Price / Free Cash Flow-7.15-5.74-3.82-4.34-18.46-3.39
ENTERPRISE VALUE METRICS
Enterprise Value109.3149.791.4120.3156.528.7
Enterprise Value / Sales4.616.662.332.359.771.94
Enterprise Value / EBITDA-5.18-3.67-2.36-2.19-15.14-2.53
Enterprise Value / EBIT-5.10-3.64-2.33-2.17-14.87-2.48

Financials

Full Financials
Millions USD5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue44.4%13.022.539.351.356.7
Gross Income50.6%9.417.533.043.048.3
EBITDA3.6%-40.6-40.7-38.7-54.9-46.7
EBIT3.9%-40.8-41.2-39.3-55.5-47.5
Net Income5.5%-43.1-41.4-41.2-60.0-53.3
EPS (Diluted)-84%-2.11-2.02-1.99-2.65-2.04
BALANCE SHEET
Cash & ST Inv-14.6%142.1106.290.6105.975.7
Total Assets-9%152.5124.9115.2133.4104.8
Total Liabilities77.5%6.615.839.362.465.5
Total Shareholder Equity-28%146.0109.275.971.139.3
CASH FLOW
Net Operating Cash Flow9.7%-27.7-42.7-39.0-39.1-40.2
Cap Ex-16.3%-1.2-0.7-0.6-1.4-0.6
Free Cash Flow9%-28.9-43.4-39.6-40.5-40.8

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)1.42
Basic Shares26.54
Market Cap37.7
Diluted Shares26.36
Fully Diluted Shares Outstanding26.36
Fully Diluted Market Cap37.4
+Consolidated Debt59.4
−In-the-Money Convertible Debt—
+Capital Leases0.4
+Operating Leases—
−Cash & Equivalents-72.3
−Short-term Investments-
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value24.8

Segment data

Revenue

by Geography

  • United States92%
  • Germany8%

Related companies

Apple Inc.

AAPL US

Kla Corp

KLAC US

Medtronic Public Limited Company

MDT US

Stryker Corp

SYK US

3M Company

MMM US

Northrop Grumman Corp /DE/

NOC US

Coherent Corp.

COHR US

Boston Scientific Corp

BSX US

Lenovo Group Ltd

LNVGY US

Garmin Ltd

GRMN US

HOYA Corporation

HOCPY US

Becton Dickinson & Co

0R19 LN